HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Sanofi-Aventis: The French company has a "good basis" to expand its OTC presence globally from its current position that is a "little bit overlooked," but generates about $775 million in annual sales, Executive VP for Pharmaceutical Operations Hanspeter Spek says during the firm's July 31 earnings call. Several of Sanofi's brands, including OTC laxative Maalox, are close to reaching global status, he notes. Sanofi reported its fiscal 2008 second-quarter earnings a week after announcing plans to purchase Australia's leading vitamin and mineral supplements firm, Primary Health Care's Symbion Consumer unit, for $521.4 million (1"The Tan Sheet" July 28, 2008, p. 17). Sanofi reported its net sales grew 5.2 percent to 2.73 billion euros ($10.43 billion under July 31 conversion rates) excluding the impact of currency and acquisitions. Sanofi's adjusted net income was flat at $2.73 billion...

You may also be interested in...



For Nutraceutical International, Growth Is Synonymous With Diversification

Change is a constant for Nutraceutical International. The firm annually adds about 200 nutritional supplement and natural food products to its line of brands, primarily through development but also through acquisitions

Sales & Earnings In Brief

PacificHealth: Second-quarter revenues for PacificHealth Laboratories, Inc. increased 15 percent to $2.37 million compared to $2.07 million in the prior year's period. For the April-June period in its fiscal 2008, the Matawan, N.J.-based firm records a net loss of $146,608 compared to a net loss of $127,276 last year. PacificHealth says its focus has been base business growth and increased efficiency. "Achieving 15 percent revenue growth for the second quarter, moving our gross profit margin from 37.3 percent to 45 percent for the half year, and ongoing working capital improvements is clear evidence that we are executing what we set out to achieve," the firm says. For the first six months of its fiscal year, revenues were $4.09 million compared to $3.88 million for the same period. The firm also says it is planning "significant innovation" in 2009

Sanofi-Aventis Nurtures Supplement Interest With Symbion Consumer Buy

The dietary supplement market's attraction to pharmaceutical firms surfaces again with Sanofi-Aventis acquiring Australia's leading vitamin and mineral supplements company, Primary Health Care's Symbion Consumer business

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS137152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel